Medication abortions among New York City Residents, 2001-2008

Perspectives on Sexual and Reproductive Health

Volumn 43, Issue 4, 2011, Pages 218-223

  Yunzal Butler, Cristina ^a   Sackoff, Judith ^a   Li, Wenhui ^b  

^a Department of Health and Mental Hygiene   (United States)

^b Bureau of Vital Statistics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABORTIVE AGENT; MIFEPRISTONE;

ARTICLE; ECONOMICS; EDUCATIONAL STATUS; FEMALE; HEALTH CARE DELIVERY; HEALTH SURVEY; HUMAN; INDUCED ABORTION; PREGNANCY; SOCIOECONOMICS; STATISTICS; UNITED STATES;

ABORTIFACIENT AGENTS; ABORTIFACIENT AGENTS, STEROIDAL; ABORTION, INDUCED; EDUCATIONAL STATUS; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; MIFEPRISTONE; NEW YORK CITY; POPULATION SURVEILLANCE; PREGNANCY; SOCIOECONOMIC FACTORS;

EID: 83555174854     PISSN: 15386341     EISSN: 19312393     Source Type: Journal    
DOI: 10.1363/4321811     Document Type: Article

References (25)

1. Jones RK and Henshaw SK, Mifepristone for early medical abortion: experiences in France, Great Britain and Sweden, Perspectives on Sexual and Reproductive Health, 2002, 34(3):154-161.
2. Koonin LM, Abortion reporting in the era of medical procedures: Why is it important? Journal of the American Medical Women's Association, 2000, 55(3 Suppl.):203-204.
3. Boonstra H, Mifepristone in the United States: status and future, Guttmacher Report on Public Policy, 2002, 5(3):4-7.
4. Jones RK et al., Trends in abortion in the United States, Clinical Obstetrics and Gynecology, 2009, 52(2):119-129.
5. Elam-Evans LD et al., Abortion surveillance-United States, 1999, Morbidity and Mortality Weekly Report, 2002, Vol. 51, No. SS-9.
6. Jones RK and Kooistra K, Abortion incidence and access to services in the United States, 2008, Perspectives on Sexual and Reproductive Health, 2011, 43(1):41-50.
7. Pazol K et al., Abortion surveillance-United States, 2006, Morbidity and Mortality Weekly Report, 2009, Vol. 58, No. SS-8.
8. Berer M, Why medical abortion is important for women, Reproductive Health Matters, 2005, 13(26):6-10.
9. New York City Department of Health and Mental Hygiene, Summary of Vital Statistics 2008, the City of New York, 2010, <>, accessed Nov. 22, 2010.
10. Jones RK et al., Abortion in the United States: incidence and access to services, 2005, Perspectives on Sexual and Reproductive Health, 2008, 40(1):6-16.
11. Elam-Evans LD et al., Abortion surveillance-United States, 2000, Morbidity and Mortality Weekly Report, 2003, Vol. 52, No. SS-12.
12. Strauss LT et al., Abortion surveillance-United States, 2001, Morbidity and Mortality Weekly Report, 2004, Vol. 53, No. SS-9.
13. Strauss LT et al., Abortion surveillance-United States, 2003, Morbidity and Mortality Weekly Report, 2006, Vol. 55, No. SS-11.
14. Strauss LT et al., Abortion surveillance-United States, 2004, Morbidity and Mortality Weekly Report, 2007, Vol. 56, No. SS-9.
15. Strauss LT et al., Abortion surveillance-United States, 2002, Morbidity and Mortality Weekly Report, 2005, Vol. 54, No. SS-7.
16. Henshaw SK and Finer LB, The accessibility of abortion services in the United States, 2001, Perspectives on Sexual and Reproductive Health, 2003, 35(1):16-24.
17. Unpublished data from the New York City Bureau of Maternal, Infant and Reproductive Health, 2011.
18. Beckman LJ and Harvey SM, Experience and acceptability of medical abortion with mifepristone and misoprostol among U.S. women, Women's Health Issues, 1997, 7(4):253-262.
19. Teal SB, Dempsey-Fanning A and Westhoff C, Predictors of acceptability of medication abortion, Contraception, 2007, 75(3):224-229.
20. Clark S, Ellertson C and Winikoff B, Is medical abortion acceptable to all American women: the impact of sociodemographic characteristics on the acceptability of mifepristone-misoprostol abortion, Journal of the American Medical Women's Association, 2000, 55(3 Suppl.):177-182.
21. Bazelon E, The new abortion providers, New York Times Magazine, July 18, 2010, <>, accessed Aug. 12, 2010.
22. Harper CC, Henderson JT and Darney PD, Abortion in the United States, Annual Review of Public Health, 2005, 26:501-512.
23. Leeman L et al., Can mifepristone medication abortion be successfully integrated into medical practices that do not offer surgical abortion? Contraception, 2007, 76(2):96-100.
24. Finer LB and Wei J, Effect of mifepristone on abortion access in the United States, Obstetrics & Gynecology, 2009, 114(3):623-630.
25. Dehlendorf CE and Grumbach K, Medical liability insurance as a barrier to the provision of abortion services in family medicine, American Journal of Public Health, 2008, 98(10):1770-1774.